Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR.

According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years.

Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life.

Key Takeaways from the Market Study 

  • The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022.
  • From 2023 to 2033, the global Sandhoff Disease Therapeutics market is predicted to increase at a 6% CAGR.
  • Sandhoff Disease Therapeutics Market is anticipated to be worth US$ 17.91 million by 2033.
  • Hospitals have the biggest market share, according to an FMI analysis.
  • The North American Sandhoff Disease Therapeutics market is estimated to account for 40% of the total.
  • The Asia Pacific market is likely to grow fast over the forecast period, accounting for 20% of the total. 

Market Competition

Key players in the market include pharmaceutical companies such as Bioasis Technologies Inc, Nuo Therapeutics Inc, Sio Gene Therapies, Inc., INTRABIO IRELAND LIMITED, Sanofi, ROIVANT SCIENCES LTD, Azafaros, Polaryx Therapeutics, Abbott Medtronic, and Merck & Co., Inc. along with healthcare providers and technology companies among other global players.

Read More@ https://www.futuremarketinsights.com/reports/sandhoff-disease-therapeutics-market

Key Segments Profiled in the Sandhoff Disease Therapeutics Industry Survey

Therapy:

  • Gene Therapy
  • Enzyme Replacement Therapy
  • Stem Cell Therapy

Type:

  • Acute infantile Sandhoff disease
  • Subacute juvenile Sandhoff disease
  • Late-onset Sandhoff disease

End-Users:

  • Hospitals
  • Homecare
  • Specialty Clinics

Comments

Post a Comment

Popular posts from this blog

Handheld Ultrasound Scanners Market Will Generate Booming Growth Opportunities to 2032

Image
According to industry predictions, the global Handheld Ultrasound Scanners Market Demand will increase at a CAGR of 9.1% from 2022 to 2032, reaching a value of US$ 472.1 million by the end of 2022. By 2032, sales are estimated to exceed a valuation of roughly US$ 1.1 billion. With an expected 83.6% market share in 2021, the wired modality now leads the sector. Because they connect to Bluetooth or Wi-Fi devices such as mobile phones or tablets, Handheld Ultrasound Scanners are gaining appeal among both medical professionals and non-radiologists. These devices improve networking systems and ease picture transfer to medical facilities. Global Handheld Ultrasound Scanners Market: Dynamics         Technological advancements in medical imaging devices, increased use of Handheld Ultrasound Scanners among non-radiologists, benefits from international trade agreements, increased importing of imaging diagnostics systems, increased use of Handheld Ultrasound Scanners in emergency medical service
Read more

Antidiabetics Market to reach US$ 223 billion by 2032, growing at a 9.6% CAGR from 2022 to 2032 | Future Market Insights, Inc.

Image
The global Antidiabetics Market is expected to earn US$ 223 billion while expanding at a CAGR of 9.6% during the forecast period. The rising prevalence of diabetes worldwide can be attributed to the market's expansion. The ageing baby boomer population is another factor driving the market during the forecast period. According to the International Diabetes Federation, the global diabetes incidence will increase from 366 million in 2011 to 552 million by 2030. During the forecast period, the industry is expected to benefit from a significant increase in the number of diabetic patients. Furthermore, new product development is expected to benefit the market in the near future. For example, Novo Nordisk, a Danish pharmaceutical company, announced the launch of oral semaglutide for the treatment of Type 2 diabetes in India in January 2022. Furthermore, the development of advanced pumps based on smart technologies like AI and ML is expected to open up a slew of new doors. For exampl
Read more